— Minerva Neurosciences Inc. (NASDAQ: NERV) reported a fourth-quarter 2019 loss of $29.9 million or $0.77 per share, wider than a loss of $13.2 million or $0.34 per share a year ago. Analysts estimated a loss of $0.38 per share.
— Research and development expenses jumped by 217% due to non-cash impairment expense for discontinued development of MIN-117 as well as higher development expenses for the phase 3 clinical trial of roluperidone and the phase 2b clinical trial of MIN-117.

— Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2019, decreased by 48% to $46 million from a year earlier.
— The company confirmed its previous forecast that top-line results from the Phase 3 trial with roluperidone are expected in the second quarter of 2020.
— Minerva announced positive data readouts in three-phase 2b studies and one phase 1b trial with seltorexant (MIN-202) during 2019. Three of these trials were in major depressive disorder (MDD) and one was in insomnia disorder.
— The company is currently in discussions with its partner, Janssen Pharmaceutica NV, regarding the phase 3 strategic development program for seltorexant, with a target indication of adjunctive treatment of MDD in patients with insomnia symptoms.
— The company is developing MIN-301, a pre-clinical candidate for the potential treatment of Parkinson’s disease and other neurodegenerative disorders. The company is continuing to conduct pre-clinical studies in preparation for regulatory filings leading toward entry into humans.
Most Popular
What to look for when Hormel Foods (HRL) reports Q4 2023 earnings
Shares of Hormel Foods Corporation (NYSE: HRL) were down over 1% on Monday. The stock has dropped 29% year-to-date. The food company is set to report its fourth quarter 2023 earnings
Kroger set to report Q3 results. Here’s everything you need to know
The Kroger Co. (NYSE: KR), a leading grocery retailer that operates both in-store and online, will be reporting earnings this week. The company, which is preparing to acquire rival retailer
Earnings Preview: Salesforce will likely deliver another strong quarter
Salesforce, Inc. (NYSE: CRM) achieved accelerated sales growth and profitability in recent quarters, in line with its transformation goal. The customer relationship management platform bets on new opportunities in generative